Ten-Year Outcomes Of Intensity-Modulated Radiotherapy (IMRT) Combine With Chemotherapy Versus IMRT Alone For Stage II Nasopharyngeal Carcinoma In The Real-World Study (RWD)

References

• Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011;30(2):114–119.21272443
   PubMedGoogle Scholar
• Chua DT, Ma J, Sham JS, et al. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: subgroup analysis of two Phase III trials. Int J Radiat Oncol Biol Phys. 2006;65(5):1300–1306. doi:10.1016/j.ijrobp.2006.02.01616750333
   PubMed Web of Science ®Google Scholar
• Wu LR, Liu YT, Jiang N. et al. Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: an analysis of 614 patients from a single center. Oral Oncol;2017 26–32. doi:10.1016/j.oraloncology.2017.03.015
   PubMedGoogle Scholar
• Chen Q, Han L, Lu J, et al. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer. 2010;10(1):39. doi:10.1186/1471-2407-10-66320146823
   PubMedGoogle Scholar
• Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16(4):1310–1317. doi:10.1200/JCO.1998.16.4.13109552031
   PubMed Web of Science ®Google Scholar
• Wang M, Tian H, Li G, et al. Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials. Oncotarget. 2016;7(30):48375–48390. doi:10.18632/oncotarget.1023727356743
   PubMedGoogle Scholar
• Cheng SH, Tsai SY, Yen KL, et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol Of J Am Soci Clin Oncol. 2000;18(10):2040. doi:10.1200/JCO.2000.18.10.2059
   PubMed Web of Science ®Google Scholar
• Xiao WW, Han F, Lu TX, et al. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2009;74(4):1070–1076. doi:10.1016/j.ijrobp.2008.09.00819231110
   PubMed Web of Science ®Google Scholar
• Xu T, Hu C, Wang X, et al. Role of chemoradiotherapy in intermediate prognosis nasopharyngeal carcinoma. Oral Oncol. 2011;47(5):408–413. doi:10.1016/j.oraloncology.2011.03.00821459659
   PubMed Web of Science ®Google Scholar
• Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53(1):12–22. doi:10.1016/s0360-3016(02)02724-412007936
   PubMed Web of Science ®Google Scholar
• Kam MK, Teo PM, Chau RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2004;60(5):1440–1450. doi:10.1016/j.ijrobp.2004.05.02215590175
   PubMed Web of Science ®Google Scholar
• Tham IW, Lin S, Pan J, et al. Intensity-modulated radiation therapy without concurrent chemotherapy for stage IIb nasopharyngeal cancer. Am J Clin Oncol. 2010;33(3):294–299. doi:10.1097/COC.0b013e3181d2edab20395788
   PubMed Web of Science ®Google Scholar
• Su SF, Han F, Zhao C, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys. 2012;82(1):327–333. doi:10.1016/j.ijrobp.2010.09.01121035959
   PubMed Web of Science ®Google Scholar
• Chen K, Zhu X, Li L, et al. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma. Oncotarget. 2016;7(42):69041–69050. doi:10.18632/oncotarget.1197827634892
   PubMedGoogle Scholar
• Su Z, Mao YP, Tang J, et al. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study. Tumor Biol. 2016;37(4):4429–4438. doi:10.1007/s13277-015-4266-5
   PubMedGoogle Scholar
• Zhang LN, Gao YH, Lan XW, et al. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. Oncotarget. 2015;6(41):44019–44029. doi:10.18632/oncotarget.580626528755
   PubMedGoogle Scholar
• Joseph W, Eng Huat T, Bee Choo T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol Of J Am Soci Clin Oncol. 2005;23(27):6730–6738. doi:10.1200/JCO.2005.16.790
   PubMed Web of Science ®Google Scholar
• Al-Sarraf M, Leblanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16(4):1310–1317. doi:10.1200/JCO.1998.16.4.13109552031
   PubMed Web of Science ®Google Scholar
• Chen QY, Wen YF, Guo L, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011;103(23):1761–1770. doi:10.1093/jnci/djr43222056739
   PubMed Web of Science ®Google Scholar
• Adelstein D, Gillison ML, Pfister DG, et al. NCCN guidelines insights: head and neck cancers, version 2.2017. J Natl Compr Canc Netw. 2017;15(6):761–770. doi:10.6004/jnccn.2017.010128596256
   PubMed Web of Science ®Google Scholar
• Chua DTT, Ma J, Sham JST, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol Of J Am Soci Clin Oncol. 2005;23(6):1118–1124. doi:10.1200/JCO.2005.12.081
   PubMed Web of Science ®Google Scholar
• Lin S, Lu JJ, Han L, et al. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer. 2010;10:39. doi:10.1186/1471-2407-10-66320146823
   PubMed Web of Science ®Google Scholar
• Luo S, Zhao L, Wang J, et al. Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of China. Head Neck. 2014;36(6):841–847. doi:10.1002/hed.2338623720240
   PubMed Web of Science ®Google Scholar
• Guo Q, Lu T, Lin S, et al. Long-term survival of nasopharyngeal carcinoma patients with Stage II in intensity-modulated radiation therapy era. Jpn J Clin Oncol. 2016;46(3):241–247. doi:10.1093/jjco/hyv19226755831
   PubMed Web of Science ®Google Scholar
• Kang MK, Oh D, Cho KH, et al. ERRATUM: role of chemotherapy in stage II nasopharyngeal carcinoma treated with curative radiotherapy. Cancer Res Treat Off J Korean Cancer Assoc. 2016;48(1):425. doi:10.4143/crt.2014.141.2
   PubMed Web of Science ®Google Scholar
• Efron B. The Jackknife, the Bootstrap, and Other Resampling Plans [M]. Philadelphia: SIAM; 1982.
   Google Scholar
• Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631–637. doi:10.1200/JCO.2003.06.15812586799
   PubMed Web of Science ®Google Scholar
• Chua DT, Sham JS, Kwong DL, Au GK. Treatment outcome after radiotherapy alone for patients with Stage I-II nasopharyngeal carcinoma. Cancer. 2010;98(1):74–80. doi:10.1002/cncr.11485
   Google Scholar
• Andersson-Anvret M, Forsby N, Klein G. Nasopharyngeal carcinoma. Prog Exp Tumor Res. 1978;21(1):100.205903
   PubMedGoogle Scholar
• Katano A, Takahashi W, Yamashita H, et al. Radiotherapy alone and with concurrent chemotherapy for nasopharyngeal carcinoma: a retrospective study. Medicine (Baltimore). 2018;97(18):e0502. doi:10.1097/MD.000000000001050229718841
   PubMed Web of Science ®Google Scholar
• Cheng SH, Tsai SY, Yen KL, et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol Of J Am Soci Clin Oncol. 2000;18(10):2040. doi:10.1200/JCO.2000.18.10.2059
   PubMed Web of Science ®Google Scholar
• Fangzheng W, Chuner J, Quanquan S, et al. Addition of chemotherapy to intensity-modulated radiotherapy does not improve survival in stage II nasopharyngeal carcinoma patients. J Cancer. 2018;9(11):2030–2037. doi:10.7150/jca.2504229896288
   PubMed Web of Science ®Google Scholar
• Lee AWM, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992;23(2):261–270. doi:10.1016/0360-3016(92)90740-91587745
   PubMed Web of Science ®Google Scholar
• Xu T, Shen C, Zhu G, Hu C. Omission of chemotherapy in early stage nasopharyngeal carcinoma treated with IMRT: a paired cohort study. Medicine. 2015;94(39):e1457. doi:10.1097/MD.000000000000087426426610
   PubMed Web of Science ®Google Scholar
• Chen KH, Zhu XD, Li L, et al. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma. Oncotarget. 2016;7(42):69041–69050. doi:10.18632/oncotarget.1197827634892
   PubMedGoogle Scholar